Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
January 30, 2018
Sierra Oncology to Present at the DNA Damage Response Therapeutics Summit
VANCOUVER, Jan. 29, 2018 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for ...
January 30, 2018
CymaBay Announces Pricing of Public Offering of Common Stock
NEWARK, Calif., Jan. 30, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic ...
January 30, 2018
BioDelivery Sciences Announces Launch and Availability of BELBUCA® in Canada
RALEIGH, N.C., Jan. 30, 2018 (GLOBE NEWSWIRE) --BioDelivery Sciences International, Inc. (BDSI) and Purdue Pharma (Canada) announced today that BELBUCA® (buprenorphine) buccal film is now ...
January 29, 2018
ABIVAX Appoints Carol L. Brosgart, M.D. to its Board of Directors
PARIS, Jan. 29, 2018, 8 a.m. CET – ABIVAX (Euronext Paris: FR0012333284 – ABVX), a biotechnology company harnessing the immune system to develop a functional cure ...
January 29, 2018
Prometic's PBI-4050: Phase 3 Pivotal Clinical Trial Design For Idiopathic Pulmonary Fibrosis (IPF) Finalized
LAVAL, QC, Jan. 29, 2018 /PRNewswire/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) ("Prometic") announces today the outcome of a successful clinical development Type C meeting with the US ...
January 29, 2018
Renevia® Data From the Successful Pivotal Trial to Be Presented at the IMCAS Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that detailed data from the ...
January 29, 2018
Aradigm Receives Complete Response Letter from the FDA for Linhaliq NDA
HAYWARD, Calif.--(BUSINESS WIRE)--Aradigm Corporation (ARDM) (the “Company”) today announces that it received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) regarding ...
January 29, 2018
Pernix Announces Patent Litigation Settlement Agreement with Actavis Concerning Zohydro® ER
MORRISTOWN, N.J., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (PTX), a specialty pharmaceutical company, today announced that it has entered into a ...
January 29, 2018
Rexahn Pharmaceuticals Receives Notice of Allowance for A New U.S. Patent Covering the Use of RX-5902 (Supinoxin™)
ROCKVILLE, Md., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment ...
January 29, 2018
Data Highlighting Advaxis’ Antigen Delivery Platform Accepted for Multiple Presentations at 2018 Keystone Symposia Conference on Cancer Immunotherapies
PRINCETON , N.J.--(BUSINESS WIRE)--Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that three abstracts highlighting the ...
January 29, 2018
Bellerophon Therapeutics Announces Enrollment Exceeds 100 Patients in Phase 3 INOvation-1 Study Evaluating INOpulse® for Treatment of Pulmonary Arterial Hypertension
WARREN, N.J., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company, today announced that enrollment in its Phase 3 INOvation-1 study ...
January 26, 2018
Prometic to host Key Opinion Leader meeting on novel treatments for idiopathic pulmonary fibrosis (IPF)
LAVAL, QC , Jan. 25, 2018 /CNW/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF)("Prometic") announced  that it will host a Key Opinion Leader (KOL) meeting on ...
January 26, 2018
Onxeo Receives EPO Intent-to-Grant Notice for Key AsiDNA™ Patent, Extending IP Protection in Europe Until 2031
PARIS--(BUSINESS WIRE)--Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO - FR0010095596), (“Onxeo” or the “Company”), a biotechnology company specializing in the development of innovative drugs ...
January 26, 2018
ESSA Announces Management Team Change
HOUSTON and VANCOUVER , Jan. 25, 2018 /CNW/ - ESSA Pharma Inc. (TSXV: EPI; Nasdaq: EPIX) ("ESSA" or the "Company") announced today that  Frank Perabo, ...
January 26, 2018
Santhera Receives Negative CHMP Opinion on Appeal for Authorization of Raxone® in Duchenne Muscular Dystrophy
Liestal, Switzerland, January 26, 2018 - Santhera Pharmaceuticals (SIX: SANN) announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ...
January 26, 2018
ESSA to Present at Noble Capital Markets' NobleCon14
HOUSTON and VANCOUVER, Jan. 26, 2018 /PRNewswire/ - ESSA Pharma Inc. (TSXV: EPI; Nasdaq: EPIX) ("ESSA" or the "Company") today announced that David R. Parkinson, ...
January 25, 2018
Advaxis’ Immunotherapy in Combination with Chemoradiation Highlighted as Potential Treatment for Anal Cancer in International Journal of Radiation Oncology
PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announces that data from the investigator-initiated ...
January 25, 2018
Albireo Prices $65.0 Million Public Offering of Common Stock
BOSTON, Jan. 25, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today ...
January 25, 2018
OSE Immunotherapeutics Receives Notice of Allowance for New Patent by U.S. Patent and Trademark Office that Further Strengthens Intellectual Property Portfolio Around Tedopi® in Immuno-Oncology Applications
NANTES, France, Jan. 25, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics(ISIN:FR0012127173) (Mnémo:OSE), today announces that it has received a notice of allowance from the U.S. Patent ...
January 25, 2018
Zealand Pharma hosts Capital Market Day: Accelerating the late stage pipeline
Copenhagen 25 January, 2018 - Zealand Pharma (Zealand) will host a Capital Market Day in New York, starting at 12:30 pm ET (6.30 pm CET), ...
Page 90 of 138